Psoriasis causes high costs, reduces productivity at work and quality of life;Psoriasis verursacht hohe Kosten, mindert die Produktivität am Arbeitsplatz und verringert die Lebensqualität

Aktuelle Dermatologie

Volumn 37, Issue 10, 2011, Pages 353-359

  Augustin, M ^a   Chapnik, J ^b   Gupta, S ^b   Buesch, K ^c   Radtke, M ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Consumer Health Sciences ^*  (United States)

^c ABBOTT GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COST OF ILLNESS; DISEASE SEVERITY; GERMANY; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; PREVALENCE; PRODUCTIVITY; PSORIASIS; QUALITY OF LIFE;

EID: 80053508978     PISSN: 03402541     EISSN: 1438938X     Source Type: Journal    
DOI: 10.1055/s-0030-1256636     Document Type: Article

References (36)

1. Augustin M, Glaeske G, Radtke M A. et al. Epidemiology and comorbidity of psoriasis in children. Br J Dermatol 2010 162 (3) 633-636
2. Augustin M, Krüger K, Radtke M A., Schwippl I, Reich K. Disease Severity, Quality of Life and Health Care in Plaque-Type Psoriasis: A Multicenter Prospective Cross-Sectional Study in Germany. Dermatology 2008 216 366-372 (Pubitemid 351630108)
3. Augustin M, Reich K, Glaeske G, Schaefer I, Radtke M. Comorbidity and age-related prevalence of psoriasis analysis of health insurance data in Germany. Acta Derm Venereol 2010 90 147-151
4. Augustin M, Reich K, Reusch M et al. Health services research in psoriasis the German approach. Dermatology 2009 218 (4) 293-301
5. Berger K, Ehlken B, Kugland B, Augustin M. Cost-of-illness in patients with moderate and severe chronic psoriasis vulgaris in Germany. J Dtsch Dermatol Ges 2005 3 (7) 511-518 (Pubitemid 40942633)
6. Bullinger M, Kirchberger I. SF-36. Fragebogen zum Gesundheitszustand. Göttingen Hogrefe 1998
7. Consumer Health Sciences (CHS). Im Internet: www.chsinternational.com Stand: 15.09.2009
8. Delfino M Jr, Holt E W., Taylor C R., Wittenberg E, Qureshi A A. Willingness-to-pay stated preferences for 8 health-related quality-of-life domains in psoriasis: a pilot study. J Am Acad Dermatol 2008 59 (3) 439-447
9. Jiménez-Puya R, Gómez-García F, Amorrich-Campos V, Moreno-Giménez J C. Etanercept: Efficacy and safety. J Eur Acad Dermatol Venereol 2009 23 (4) 402-405
10. Gelfand J M., Troxel A B., Lewis J D. et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol 2007 143 (12) 1493-1499 (Pubitemid 350277763)
11. Griffiths C EM, Camp R DR, Barker J NWN. Rook's textbook of dermatology. 7th ed. Oxford Blackwell 2005
12. Kimball A B., Jacobson C, Weiss S, Vreeland M G., Wu Y. The psychosocial burden of psoriasis. Am J Clin Dermatol 2005 6 (6) 383-92 (Pubitemid 43128290)
13. Krüger G, Koo J, Lebwohl M et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001 137 (3) 280-284 (Pubitemid 32240779)
14. Krüger G G., Feldman S R., Camisa C et al. Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol 2000 43 (2 Pt 1) 281-5 (Pubitemid 30626007)
15. Kurd S K., Gelfand J M. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 20032004. 2009 60 (2) 218-24
16. Mrowietz U, Elder J T., Barker J. The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients. Arch Dermatol Res 2006 298 (7) 309-319
17. Nast A et al. S3-Leitlinie zur Therapie der Psoriasis vulgaris. J Dtsch Dermatol Ges 2011
18. Nelson A A., Pearce D J., Fleischer A B. Jr, Balkrishnan R, Feldman S R. Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period. J Am Acad Dermatol 2008 58 (1) 125-35 (Pubitemid 350298147)
19. Official figures by the Federal Statistical Bureau on average stays in rehabilitation care in the ICD 10 code L40. Im Internet: http://www.gbe-bund.de/ oowa921-install/servlet/oowa/aw92/dboowasys921.xwdevkit/xwd-init?gbe. isgbetol/xs-start-neu/i95479111/47809735 Stand: 15. 09. 2009
20. Radtke M A., Augustin M. Effiziente Kontrolle erforderlich. Kosten und Wirtschaftlichkeit der Psoriasis-Therapie. Gesellschaftspolitische Kommentare 2008 1 26-29
21. Radtke M A., Reich K, Blome C, Rustenbach S, Augustin M. Prevalence and clinical features of psoriatic arthritis and joint complaints in 2009 patients with psoriasis: results of a German national survey. J Eur Acad Dermatol Venereol 2009 23 (6) 683-91
22. Radtke M, Reich K, Reich C et al. Evaluation of quality of care and guideline-compliant treatment in psoriasis: development of a new system of quality indicators. Dermatology 2009 219 (1) 54-8
23. Rapp S R., Feldman S R., Exum M L., Fleischer A B. Jr, Reboussin D M. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999 41 (3 Pt 1) 401-7 (Pubitemid 29418506)
24. Reich K, Krüger K, Mössner R, Augustin M. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol 2009 160 (5) 1040-7
25. Reilly M C., Zbrozek A S., Dukes E M. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993 4 (5) 353-365
26. Revicki D A., Menter A, Feldman S et al. Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled Phase III study. Health Qual Life Outcomes 2008 6 75
27. Schäfer I, Hacker J, Rustenbach S J. et al. Concordance of the Psoriasis Area and Severity Index (PASI) and patient-reported outcomes in psoriasis treatment. Eur J Dermatol 2010 20 (1) 62-67
28. Schäfer I, Rustenbach S J., Zimmer L, Augustin M. Prevalence of skin diseases in a cohort of 48,665 employees in Germany. Dermatology 2008 217 (2) 169-172
29. Schmid-Ott G, Künsebeck H W., Jäger B et al. Significance of the stigmatization experience of psoriasis patients: a 1-year follow-up of the illness and its psychosocial consequences in men and women. Acta Derm Venereol 2005 85 (1) 27-32 (Pubitemid 40254676)
30. Schöffski O, Augustin M, Prinz J et al. Costs and quality of life in patients with moderate to severe plaque-type psoriasis in Germany: a multi-center study. J Dtsch Dermatol Ges 2007 5 (3) 209-218 (Pubitemid 46361354)
31. Sizto S, Bansback N, Feldman S R., Willian M K., Anis A H. Economic evaluation of systemic therapies for moderate to severe psoriasis. Br J Dermatol 2009 160 (6) 1264-72
32. Sohn S, Schöffski O, Prinz J et al. Cost of moderate to severe plaque psoriasis in Germany: a multicenter cost-of-illness study. Dermatology 2006 212 (2) 137-144 (Pubitemid 43260729)
33. Stern R S., Nijsten T, Feldman S R. et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 2004 9 136-139 (Pubitemid 38457271)
34. United States Census Bureau and Organization for Economic Cooperation and Development, International Database (2007). Im Internet: http://www.census.gov Stand: 20.08.2009
35. Ware J E., Kosinski M, Turner-Bowker D M., Gandek B. How to score Version 2 of the SF-12 Health Survey (with a supplement documenting version 1). Health Assessment Lab 2002
36. Zachariae R, Zachariae C, Ibsen H H., Mortensen J T., Wulf H C. Psychological symptoms and quality of life of dermatology outpatients and hospitalized dermatology patients. 2002 84 (3) 205-212